Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 1.04 (7.79%)
Data as of 09/29/16 12:29 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
09/26/16Exelixis Elects Julie Anne Smith to Its Board of DirectorsPrinter Friendly Version
09/26/16Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor AntagonistPrinter Friendly Version
09/20/16Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 CongressPrinter Friendly Version
09/14/16European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted TherapyPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.